Alto Neuroscience presents ALTO-207 development plans for treatment-resistant depression
ANRO•Alto Neuroscience expects Phase 2b topline data for ALTO-207 in the second half of 2027, with Phase 3 trials planned to start in early 2027 and the second half. The company expects cash to last through 2030 and anticipates five late-stage data readouts over approximately three years.
1. Development timeline
Alto Neuroscience expects Phase 2b topline data for ALTO-207 in treatment-resistant depression in the second half of 2027. It plans to begin an adjunctive Phase 3 trial in early 2027 and a monotherapy Phase 3 trial in the second half. Phase 2b data for ALTO-300 in depression are expected in the first half of 2027, while ALTO-100 bipolar depression data are due midyear. The company expects its cash runway to extend through 2030 and anticipates five late-stage data readouts over approximately three years.
